Carlos Coronell - WIZBII Carlos Coronell ha publicado su perfil profesional en WIZBII. C C

Carlos Coronell

MD with more than 13 year in the Pharmaceutical Business

58 años • Barcelona

Currículum

Highly accomplished International Pharmaceutical Medical Executive with almost 13 years of experience: 1) Leadership: Led cross-functional operating units/teams at 3 levels: regional, country and internationally in conjunction of products with GMA. Line Management experience mentoring MSLs. 2) Business acumen: Successful medical/scientific communication in all levels, matrix environments. Close interaction with Commercial Departments. Expertise in pre-launch, launch and Life cycle management of the products. 3) Adaptable: Continuous record of successful performance:

Competencias

Objective OrientedPatient OrientedPositiveProblem SolverMedical AffairsClinical Development

Experiencias

European Independent Consultant on Cancer Clinical Development Program

10-2016 - AhoraServicios personales• Led and developed of Phase I, II and III clinical trials for different molecules and tumors (brigatinib for lung cancer [NSCLC ALK+]; olaparib for endometrial cancer; osimertinib for NSCLC + EGFR T790M; Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer; ruxolitinib versus best available therapy in patients with Polycythemia Vera who are hydroxyurea resistant or intolerant; ruxolitinib for patients with primary myelofibrosis (PMF) or post-polycythemia vera myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibrosis (PET-MF)). • Maintain bilateral communication and solid professional relationships between site PIs, investigator teams, KOLs and Pharmaceutical’s medical department to support the medical/scientific information and research needs. • Develop and conduct training sessions on scientific/medical information at specific training events and site initiation visits.

European Medical Affairs Manager

05-2016 - 10-2016 Servicios personales• Provide strategic and tactical medico-scientific advice and expertise supporting the Dysport™ European Business Unit, in line with the Neurology Franchise brand strategy. Working with adult muscle spasticity, cervical dystonia and cerebral palsy as indications of botulinum toxin A (AbobotulinumtoxinA, Dysport™). Suggest, direct and manage new medical, scientific, and clinical trial and communication initiatives that will support and help deliver medium and long-term profitable business growth, within the strategic framework of the Ipsen Group.

European Regional Medical Affairs Manager

03-2015 - 04-2016 Servicios personales• Led Medical/Scientific product information awareness (IRIDICA System™), focus in clinical benefits, pharmaco-economics, and patient needs. This platform is a breakthrough technology that is used for the identification of more than 1000 pathogens (Bacteria, Fungi and Viruses). It was my responsibility to manage the introduction of this new technology among scientific and medical professionals in southern European countries (Spain, Portugal, Italy, Turkey, etc…) and eastern European countries (Romania, Poland, Czech Republic, Russia, etc…). • Communicate complex scientific data to healthcare professionals with clinical sessions or round tables at Hospital settings, lectures at national or international congresses within different therapeutic areas (Microbiology, Infectious Disease & Critical Care Medicine). • Build relationships with and present clinical data to key therapeutic area opinion leaders and customers. • Provide expert opinion in clinical data analysis and development of original scientific publications within the therapeutic area, including economic outcomes data. • Responsible for partnering with investigators in the therapeutic area to develop and execute investigator initiated studies. • Led and developed of the observational study RADICAL IMPACT, about the use of the IRIDICA System™ for the development of clinical evidence under real life conditions.

Medical Manager

03-2013 - 03-2015 Servicios personales• Led domestic scientific/medical support to belimumab (Benlysta™) for the treatment of adult patients with active systemic lupus erythematosus (SLE). • Developed effective team within 3 Medical Science Liaison (MSLs) under my supervision and mentoring. • Led and developed of Phase II and III clinical trials for several molecules (GSK2586184 for Lupus and Rheumatoid Arthritis, Mepolizumab in Eosinophilic Granulomatosis with Polyangiitis, Vercirnon [GSK1605786A] for Crohn’s Disease). • Engage locally and internationally with the External Experts (EEs), HCP’s within the activities of scientific engagement, clinical research, clinical trials, market access, payers with focus in immunotherapy and ensuring medical affairs alignment. • Provide medical input in the operational activities (Medical/Scientific) as Clinical Assays/ISSs review and Implementation (Protocol, feasibility questionnaires, site qualification/selection, with R&D projects). • Led MA program to Identify evidence gaps to address LOC unmet needs and define opportunities for data generation. • Domestic head medical/scientific support to Paediatric Vaccine Area: Infanrix Hexa™ (Combined diphtheria and tetanus toxoids, acellular pertussis, hepatitis B [recombinant], inactivated poliomyelitis and adsorbed conjugated Haemophilus influenzae type b vaccine), Boostrix™ (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed), Ditanrix™ (Vaccine anti-diphtheria and tetanus [Td]), Varilrix™ (Live attenuated varicella vaccine), Priorix™ (Measles, Mumps and Rubella vaccine [live]), Priorix Tetra™ (Combined measles, mumps, rubella and varicella vaccine, live, attenuated), Synflorix™ (10-valent adsorbed pneumococcal polysaccharide conjugate vaccine), and Rotarix™ (Rotavirus Vaccine, Live, Oral). • Led and developed an effective team with the 10 Medical Science Liaisons (MSLs) under my supervision and mentoring. • Provided successful scientific/medical engagement with the External Experts (EEs) within the activities of clinical research and commercialization. • Supported the medical evidence generation for the Vaccines Area in Spain in collaboration with Market Access, payers, HCPs, and KEEs networks. • Provided medical inputs in the operational activities (Medical/Scientific) as Clinical Assays/ISSs review and Implementation (Protocol, feasibility questionnaires, site qualification/selection, with R&D projects). • Provided scientific support to Infectious Disease area with co-amoxiclav (Augmentin™), cefditoren pivoxil (Spectracef™), cefuroxime (Zinacef™) and other antibiotic molecules. • Developed an effective team with the 3 Medical Science Liaisons (MSLs) under my supervision and mentoring.

Medical Advisor

07-2006 - 03-2013 Servicios personales• Led pre-launch and successfully launching of Dabigatran (Pradaxa™) in two consecutive indications: o Prevention of venous thromboembolic events (VTE) in patients who have undergone elective total hip replacement or total knee replacement surgery. o Prevention of stroke and systemic embolism in patients with atrial fibrillation, in who anticoagulation is appropriate. • Led the creation and developed of an effective team with the 10 Medical Science Liaisons (MSLs) under my supervision and mentoring. • Led and developed of Phase II and III clinical trials for several molecules (BIBF 1120 for Idiopathic Pulmonary Fibrosis, Pramipexole ER in Parkinson’s Disease). • Led and developed of the GLORIA-AF Registry after marketing of dabigatran on real life condition, for the generation of evidence. • Supported the Medical Strategy of Telmisartan (Micardis™) for arterial hypertension control. • Central Nervous System (CNS) area: medical/scientific support to Pramipexole (Mirapexin™) for Parkinson’s disease, with Successfully Launching of Mirapexin™ for Restless Legs Syndrome. Scientific support to duloxetine (Xeristar™) for Depression (Mayor Depressive Disorder/Minor Depressive Disorder), neuropathic pain associated with diabetic peripheral neuropathy and Anxiety; support the life cycle management of metamizole (Nolotil™) for moderate to severe pain control; and pre-marketing activities of flibanserin for Hypoactive Sexual Desire Disorder in pre-menopausal women. • Led data generation project, creating overviews, and generating ideas for new and innovative studies within Medico-Commercial activities. Preparing national and regional events, such as Advisory Board Meetings, Expert Panel Meetings and Satellite Symposia at International, National, and Regional Congresses. • Led life cycle management of the products, In-depth review of relevant literature, clinical sessions in hospitals, cross-functional collaborations, as well as extensive External Experts (KOLs) interaction and identification. • Led medical/scientific promotional review materials and approval. • Active member of the investigators sponsored studies (ISS) review and approval, post-marketing/epidemiological studies and post-marketing surveys.

Pre-Doctoral Researcher

01-2000 - 03-2006 Servicios personales• Doctoral Thesis on muscle dysfunction in patients with Chronic Obstructive Pulmonary Disease (COPD). • Muscle physiology in healthy subjects and muscle pathophysiology of patients with COPD at the peripheral and respiratory muscle levels.

Guest Researcher

05-1997 - 10-1998 Servicios personalesMajor Histocompatibility Complex (MHC/HLA) typing, in humans through molecular biology to evaluate an association among felbamate (Felbatol™) and liver failure.

Head, Immunology and Genetics Laboratory

01-1995 - 12-1999 Servicios personales• Led the immunology and genetics. • Lecturer of immunology and genetics at university settings.

Associated Researcher

01-1994 - 01-1995 Servicios personalesPreclinical and clinical research experience, and extensive background in the development and validation of immunodiagnostic techniques to detect infectious diseases (tuberculosis and leprosy) using synthetic peptides, preclinical and clinical assays of chemically synthesised vaccine against malaria (SPf66).

Formación

Universitat Pompeu Fabra

2012 - 2013 Barcelona, SpainServicios personalesDiploma in Pharmacy-Economy

Universitat Pompeu Fabra

2006 - 2008 Barcelona, Província de BarcelonaMarketingMaster in Pharmaceutical Marketing

Universitat Pompeu Fabra

2000 - 2006 Barcelona, SpainServicios personalesPhD in Biomedicine Doctoral Thesis, Cum Laude “Muscle Dysfunction in Patients with Chronic Obstructive Pulmonary Disease, COPD”

Universidad Metropolitana

1982 - 1989 San Juan, United States of AmericaServicios personalesMedical Doctor degree (MD)

Mis cualidades

Positivo/a
Perseverante
Creativo/a
Flexible

Idiomas hablados

  • Español

    Lengua materna

  • Inglés

    Profesional

  • Portugués

    Nociones

  • Italiano

    Nociones

Mi presencia en internet

Hacer que su futuro sea todo un éxito.
  • Directorio de empleos
  • Directorio de empresas